+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rare Disease Genetic Testing Market - Global Forecast 2026-2032- Product Image
Rare Disease Genetic Testing Market - Global Forecast 2026-2032- Product Image
New

Rare Disease Genetic Testing Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 189 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5533238
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The rare disease genetic testing market is transforming rapidly, integrating advanced diagnostics, regulatory shifts, and evolving operational standards. Senior decision-makers now face a complex environment where precision medicine, compliance, and resilience must align to capture long-term value and meet clinical needs.

Market Snapshot: Rare Disease Genetic Testing Market Growth

The Rare Disease Genetic Testing Market expanded from USD 1.79 billion in 2025 to USD 2.09 billion in 2026, with expectations to reach USD 5.39 billion by 2032 at a CAGR of 17.00%. This robust growth reflects increasing investment in clinical genomics, improved access to advanced diagnostics, and heightened demand for precise disease characterization. Regulatory updates, a broader reimbursement landscape, and global health initiatives further reinforce the market’s progress, creating opportunities for both established stakeholders and new market entrants.

Scope & Segmentation of the Rare Disease Genetic Testing Market

This report covers the full spectrum of rare disease genetic testing, with detailed focus on sectoral drivers and segmentation influencing current and future trends. Key areas of analysis include:

  • Technology: Next Generation Sequencing modalities, microarray analysis, and polymerase chain reaction methods (digital and quantitative PCR) driving innovation and data accuracy across clinical and research settings.
  • Test Types: Genome sequencing (including both whole and targeted applications), exome sequencing across clinical and research use, customized panel testing for oncology, cardiovascular, neurological diseases, as well as single gene analysis for rare phenotypes.
  • End Users: Diagnostic laboratories, hospitals (public and private), research institutions, and specialty clinics supporting clinical adoption and translational research.
  • Applications: Carrier screening, newborn and prenatal diagnostics (employing both non-invasive and invasive modalities), broader clinical diagnostics, and applications for biomedical research and epidemiological studies.
  • Disease Indications: Hematological disorders, metabolic diseases (such as enzyme deficiencies and mitochondrial conditions), neuromuscular syndromes, and oncological indications representing evolving areas of clinical need.
  • Geographies: Americas, Europe, Middle East & Africa (EMEA), and Asia-Pacific regions, with an emphasis on local challenges, reimbursement policies, and varying regulatory pathways influencing market access and growth.

Key Takeaways: Strategic Insights for Senior Decision-makers

  • Adoption of Next Generation Sequencing is transitioning genetic testing from single-gene approaches to extensive, multiplexed genomic analysis, broadening the scope of actionable clinical information.
  • Laboratories and manufacturers are responding to evolving payer and regulatory expectations by focusing on evidence-based outcomes, reimbursement optimization, and clear demonstration of clinical value.
  • Test suite design is increasingly shaped not only by emerging medical requirements but also by the need for supply chain flexibility and contingency planning amidst global disruptions.
  • Organizations seeking international expansion must navigate region-specific regulatory frameworks, cultivate market-specific partnerships, and customize entry strategies to address heterogeneous healthcare ecosystems.
  • The expansion of bioinformatics capacities and continuous professional development for clinicians underpin scalable adoption and support confident integration into patient care.

Tariff Impact: U.S. Policy Changes and Procurement Strategies

In 2025, updates to United States tariffs introduced additional layers of complexity for rare disease genetic testing stakeholders. To preserve operational continuity and mitigate risk, laboratories and procurement teams responded by:

  • Broadening their supplier network to enhance supply stability and manage geopolitical uncertainties.
  • Fostering domestic and regional manufacturing relationships to support agile sourcing strategies.
  • Prioritizing robust inventory controls and strategic adjustments to the test portfolio in order to avoid service bottlenecks.
  • Strengthening compliance protocols and actively managing vendor oversight during procurement and qualification stages.

Organizations adopting diversified sourcing and adaptable operating models maintained uninterrupted access to vital diagnostic technologies amid shifting import protocols and logistical pressures.

Methodology & Data Sources

This study synthesizes input from primary interviews with laboratory directors, clinical geneticists, procurement leads, and policy advisors. Supporting data includes laboratory validation analysis, technical reviews, and curated independent peer-reviewed research. Tariff and supply chain scenarios are examined to reflect actual market operating conditions.

Why This Report Matters

  • Clarifies the impact of technology innovations and changing regulatory environments on operational strategy and long-term market value in rare disease genetic testing.
  • Provides actionable insights to help decision-makers align service propositions with clinical need and payer demands, ensuring business continuity and strategic agility across global markets.
  • Equips executives and clinical leaders with the information needed to secure robust, future-proof operating models amid evolving industry, reimbursement, and compliance landscapes.

Conclusion

Rare disease genetic testing will progress through focused collaboration among innovators, healthcare leaders, and policy influencers. Long-term success will depend on operational flexibility, clinical integration, and responsive market strategies tailored to a dynamic global environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Rare Disease Genetic Testing Market, by Test Type
8.1. Exome Sequencing
8.1.1. Clinical Exome
8.1.2. Research Exome
8.2. Genome Sequencing
8.2.1. Targeted Genome
8.2.2. Whole Genome
8.3. Panel Test
8.3.1. Cancer Panels
8.3.2. Cardiovascular Panels
8.3.3. Neurological Panels
8.4. Single Gene Test
9. Rare Disease Genetic Testing Market, by Technology
9.1. Microarray
9.2. Next Generation Sequencing
9.2.1. Sequencing By Ligation
9.2.2. Sequencing By Synthesis
9.3. Polymerase Chain Reaction
9.3.1. Digital PCR
9.3.2. Quantitative PCR
10. Rare Disease Genetic Testing Market, by Disease Indication
10.1. Hematological Disorders
10.2. Metabolic Disorders
10.2.1. Enzyme Deficiencies
10.2.2. Mitochondrial Disorders
10.3. Neuromuscular Disorders
10.4. Oncology
11. Rare Disease Genetic Testing Market, by Application
11.1. Carrier Screening
11.2. Diagnostics
11.3. Newborn Screening
11.4. Prenatal Screening
11.4.1. Invasive
11.4.2. Non Invasive
11.5. Research Applications
12. Rare Disease Genetic Testing Market, by End User
12.1. Diagnostic Laboratories
12.2. Hospitals
12.2.1. Private Hospitals
12.2.2. Public Hospitals
12.3. Research Institutions
12.4. Specialty Clinics
13. Rare Disease Genetic Testing Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Rare Disease Genetic Testing Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Rare Disease Genetic Testing Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Rare Disease Genetic Testing Market
17. China Rare Disease Genetic Testing Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. 3billion, Inc.
18.6. Ambry Genetics Corporation
18.7. Arup Laboratories
18.8. Baylor Genetics
18.9. Caris Life Sciences
18.10. CENTOGENE N.V.
18.11. Color Health, Inc.
18.12. F. Hoffmann-La Roche Ltd.
18.13. Fulgent Genetics, Inc.
18.14. GeneDx, LLC
18.15. Genomelink, Inc.
18.16. Helix OpCo, LLC
18.17. Illumina, Inc.
18.18. Integrated DNA Technologies, Inc.
18.19. Invitae Corporation
18.20. Laboratory Corporation Of America Holdings
18.21. Macrogen, Inc.
18.22. Myriad Genetics, Inc.
18.23. Nonacus Limited
18.24. OPKO Health, Inc.
18.25. PerkinElmer Inc.
18.26. Progenity, Inc.
18.27. QIAGEN N.V.
18.28. Quest Diagnostics Incorporated
18.29. Realm IDX, Inc.
18.30. Sanofi S.A.
18.31. The Cooper Companies, Inc.
18.32. Thermo Fisher Scientific Inc.
18.33. Variantyx, Inc.
List of Figures
FIGURE 1. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CLINICAL EXOME, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CLINICAL EXOME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CLINICAL EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH EXOME, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH EXOME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TARGETED GENOME, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TARGETED GENOME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TARGETED GENOME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER PANELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER PANELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR PANELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR PANELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL PANELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL PANELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SINGLE GENE TEST, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SINGLE GENE TEST, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SINGLE GENE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY LIGATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY LIGATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY LIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENZYME DEFICIENCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENZYME DEFICIENCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENZYME DEFICIENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 183. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 185. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 186. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 187. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 188. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 189. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 190. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 191. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 192. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 193. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 194. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 195. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 211. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 212. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 213. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 214. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 215. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 216. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 217. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 218. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 219. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 220. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 221. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 222. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 223. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 227. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 230. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 231. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 236. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 237. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 239. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 240. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 242. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 243. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 244. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 245. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 246. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 247. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 248. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 249. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 250. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 251. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 252. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 254. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 255. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 256. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 257. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 258. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 259. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 260. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 261. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 262. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 263. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 264. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 265. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 266. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 282. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 283. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 284. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 285. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
TABLE 286. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
TABLE 287. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 288. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 289. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
TABLE 290. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 291. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 292. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 293. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
TABLE 294. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 295. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 296. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 297. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE,

Companies Mentioned

The key companies profiled in this Rare Disease Genetic Testing market report include:
  • 3billion, Inc.
  • Ambry Genetics Corporation
  • Arup Laboratories
  • Baylor Genetics
  • Caris Life Sciences
  • CENTOGENE N.V.
  • Color Health, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • GeneDx, LLC
  • Genomelink, Inc.
  • Helix OpCo, LLC
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Invitae Corporation
  • Laboratory Corporation Of America Holdings
  • Macrogen, Inc.
  • Myriad Genetics, Inc.
  • Nonacus Limited
  • OPKO Health, Inc.
  • PerkinElmer Inc.
  • Progenity, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Realm IDX, Inc.
  • Sanofi S.A.
  • The Cooper Companies, Inc.
  • Thermo Fisher Scientific Inc.
  • Variantyx, Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.09 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.39 Billion
Compound Annual Growth Rate17.0%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Rare Disease Genetic Testing Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Rare Disease Genetic Testing Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Somatic Genetic Testing Market Report 2025 - Product Image

Somatic Genetic Testing Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Genetic Testing Market Overview, 2025-2030 - Product Image

Genetic Testing Market Overview, 2025-2030

  • Report
  • 109 Pages
  • Global
From
Rare Disease Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Rare Disease Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 188 Pages
  • Global
From
Rare Disease Genetic Testing Market Report 2025 - Product Image

Rare Disease Genetic Testing Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing market is a subset of the larger Genomics market. It focuses on the diagnosis and treatment of rare genetic diseases, which are caused by mutations in a single gene. These tests are used to identify the genetic cause of a disease, as well as to predict the risk of developing a disease in the future. They can also be used to identify the best treatment options for a particular patient. The Rare Disease Genetic Testing market is growing rapidly, driven by advances in technology and the increasing availability of genetic testing services. This has enabled more accurate diagnosis and treatment of rare diseases, as well as the development of new treatments. Companies in the Rare Disease Genetic Testing market include Ambry Genetics, Invitae, Counsyl, and GeneDx. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.